BR112013007362A2 - composição farmacêutica - Google Patents

composição farmacêutica

Info

Publication number
BR112013007362A2
BR112013007362A2 BR112013007362A BR112013007362A BR112013007362A2 BR 112013007362 A2 BR112013007362 A2 BR 112013007362A2 BR 112013007362 A BR112013007362 A BR 112013007362A BR 112013007362 A BR112013007362 A BR 112013007362A BR 112013007362 A2 BR112013007362 A2 BR 112013007362A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
relates
present
improved stability
pharmaceutical
Prior art date
Application number
BR112013007362A
Other languages
English (en)
Other versions
BR112013007362B1 (pt
Inventor
Anders Nilsson
Britta Siekmann
Kazimierz Wisniewski
Mattias Malm
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43478408&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112013007362(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferring Bv filed Critical Ferring Bv
Priority to BR122021001123-0A priority Critical patent/BR122021001123B1/pt
Publication of BR112013007362A2 publication Critical patent/BR112013007362A2/pt
Publication of BR112013007362B1 publication Critical patent/BR112013007362B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Abstract

composição farmacêutica. a presente invenção refere-se a composições famacêuticas que possuem estabilidade aperfeiçoada.
BR112013007362-4A 2010-09-30 2011-09-29 composições aquosas compreendendo carbetocina, kits compreendendo tais composições e usos das mesmas BR112013007362B1 (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR122021001123-0A BR122021001123B1 (pt) 2010-09-30 2011-09-29 composição líquida e kit

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10251690.3 2010-09-30
EP10251690 2010-09-30
PCT/IB2011/002394 WO2012042371A2 (en) 2010-09-30 2011-09-29 Pharmaceutical composition

Publications (2)

Publication Number Publication Date
BR112013007362A2 true BR112013007362A2 (pt) 2016-07-12
BR112013007362B1 BR112013007362B1 (pt) 2021-05-25

Family

ID=43478408

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112013007362-4A BR112013007362B1 (pt) 2010-09-30 2011-09-29 composições aquosas compreendendo carbetocina, kits compreendendo tais composições e usos das mesmas
BR122021001123-0A BR122021001123B1 (pt) 2010-09-30 2011-09-29 composição líquida e kit

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR122021001123-0A BR122021001123B1 (pt) 2010-09-30 2011-09-29 composição líquida e kit

Country Status (26)

Country Link
US (4) US9566311B2 (pt)
EP (4) EP3246018B1 (pt)
JP (2) JP6038797B2 (pt)
KR (2) KR101919119B1 (pt)
CN (4) CN107080832B (pt)
AU (1) AU2011309762B2 (pt)
BR (2) BR112013007362B1 (pt)
CA (1) CA2812510A1 (pt)
CY (2) CY1119245T1 (pt)
DK (3) DK2621468T3 (pt)
ES (3) ES2902418T3 (pt)
HK (1) HK1246170A1 (pt)
HR (2) HRP20211969T1 (pt)
HU (3) HUE034367T2 (pt)
IL (3) IL225238B (pt)
JO (3) JO3400B1 (pt)
LT (2) LT3222272T (pt)
MX (1) MX352949B (pt)
NZ (1) NZ609719A (pt)
PL (3) PL2621468T3 (pt)
PT (3) PT3246018T (pt)
RS (2) RS62873B1 (pt)
RU (2) RU2737264C2 (pt)
SI (3) SI3246018T1 (pt)
TW (6) TWI680773B (pt)
WO (1) WO2012042371A2 (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2014149230A (ru) * 2012-05-08 2016-06-27 Дилафор Аб Лечение послеродового кровотечения (прк)
US10441627B2 (en) * 2014-09-19 2019-10-15 Ferring B.V. Method of treating prader-willi syndrome
JP6607509B2 (ja) 2014-10-01 2019-11-20 オキシトーン バイオサイエンス ビー．ブイ． 分娩制御物質を含有する口腔内崩壊性固形医薬投与単位
EP3200764B1 (en) * 2014-10-01 2020-07-22 Oxytone Bioscience B.V. Orally disintegrating solid pharmaceutical dosage unit containing a partus control substance
KR20180023884A (ko) 2015-01-07 2018-03-07 트라이제미나 인코퍼레이티드 마그네슘-함유 옥시토신 제제 및 사용 방법
WO2016162819A1 (en) * 2015-04-07 2016-10-13 Lupin Limited Stable aqueous pharmaceutical composition of anti-tnf alpha antibody
CA3020179A1 (en) 2016-04-12 2017-10-19 Trigemina, Inc. Magnesium-containing oxytocin formulations and methods of use
CN107773531B (zh) * 2016-08-31 2021-05-04 成都倍特药业股份有限公司 一种马来酸麦角新碱注射液
CN108236601B (zh) * 2016-12-23 2020-04-17 深圳翰宇药业股份有限公司 一种稳定的含卡贝缩宫素的***给药的药用组合物及其制备方法
WO2019030412A1 (en) * 2017-08-11 2019-02-14 Ferring B.V. PROCESS FOR PRODUCING PHARMACEUTICAL PREPARATION
GB201721846D0 (en) * 2017-12-22 2018-02-07 Arecor Ltd Novel composition
US11970554B2 (en) 2018-03-01 2024-04-30 Tonix Pharmaceuticals Holding Corp. Labeled oxytocin and method of manufacture and use
CN108721598B (zh) * 2018-07-03 2020-06-05 北京市新里程医药科技有限公司 一种缩宫素原料的制备方法及其药物组合物和制剂
TW202034899A (zh) * 2018-09-20 2020-10-01 克里斯托弗 Ｓ 布萊恩特 卡貝縮宮素藥品及其製備方法
WO2020061414A1 (en) * 2018-09-20 2020-03-26 Levo Therapeutics, Inc. Stable intranasal formulations of carbetocin
EP3897571A1 (en) * 2018-12-21 2021-10-27 Arecor Limited Novel composition
JP7390031B2 (ja) 2018-12-27 2023-12-01 国立大学法人金沢大学 オキシトシン誘導体及びその使用
CN110308222A (zh) * 2019-07-17 2019-10-08 武汉赛沃医药科技有限公司 一种卡贝缩宫素原料药有关物质检测方法
CN110403904A (zh) * 2019-07-26 2019-11-05 翔宇药业股份有限公司 卡贝缩宫素注射液及其应用
CN110237230A (zh) * 2019-07-31 2019-09-17 南京康舟医药科技有限公司 一种卡贝缩宫素药物组合物及其制备方法
KR20220097360A (ko) 2019-11-04 2022-07-07 훼링 비.브이. 수유 개선을 위한 메로토신의 비강내 투여
CN111012739A (zh) * 2019-12-04 2020-04-17 长春圣金诺生物制药有限公司 一种可以常温储存的含卡贝缩宫素及稳定剂的注射液
KR20240007126A (ko) 2021-03-26 2024-01-16 오티4비 연하곤란의 치료
CN114191388B (zh) * 2021-12-27 2023-06-09 苏州天马医药集团天吉生物制药有限公司 一种卡贝缩宫素制剂的制备方法
CN114712483B (zh) * 2022-05-12 2023-09-29 成都倍特药业股份有限公司 一种麦角新碱缩宫素复方注射液及其制备方法和用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5482931A (en) * 1993-06-29 1996-01-09 Ferring Ab Stabilized pharmaceutical peptide compositions
CN1109558A (zh) * 1994-11-07 1995-10-04 马文亮 装有压力表的双管气筒
SE9604341D0 (sv) * 1996-11-26 1996-11-26 Ferring Bv Hepta-peptide oxytocin analogue
ATE232741T1 (de) 1997-11-18 2003-03-15 Uni Pharma Kleon Tsetis A B E Pharmazeutische injizierbare lösungen, die paracetamol und kombinationen aus paracetamol mit anderen aktivsubstanzen enthalten
US6333313B1 (en) 1998-10-29 2001-12-25 Board Of Regents, The University Of Texas System Clinical use of oxytocin alone or in combination to treat bone disorders
US20070032410A1 (en) * 2000-01-11 2007-02-08 Atossa Healthcare, Inc. Compositions and methods for the treatment of psychiatric disorders
US6894026B1 (en) * 2000-01-11 2005-05-17 Atossa Healthcare, Inc. Long-acting oxytocin analogues for the treatment and prevention of breast cancer and psychiatric disorders
JP2001233787A (ja) * 2000-02-04 2001-08-28 Patents Exploitation Co Bv 小・中サイズのペプチド含有薬学的組成物
AT409081B (de) * 2000-02-16 2002-05-27 Gebro Pharma Gmbh Stabile, nasal, oral oder sublingual anwendbare pharmazeutische zubereitung
KR100913714B1 (ko) 2001-11-08 2009-08-24 패시트 바이오테크 코포레이션 Ｉｇｇ 항체의 안정한 액상 약학 제형물
WO2004030524A2 (en) 2002-10-03 2004-04-15 Pr Pharmaceuticals Treatment of autism and similar disorders
EP2174663A1 (en) 2003-01-08 2010-04-14 Novartis Vaccines and Diagnostics, Inc. Stabilized aqueous compositions comprising tissue factor pathway inhibitor (TFPI) or tissue factor pathway inhibitor variant
EP1605894A2 (en) 2003-03-05 2005-12-21 PR Pharmaceuticals Oxytocin controlled release formulations and methods of using same
GT200600031A (es) * 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
US20100311655A1 (en) * 2007-06-07 2010-12-09 Mdrna, Inc. Intranasal carbetocin formulations and methods for the treatment of autism
DE602008005449D1 (de) 2007-07-02 2011-04-21 Sime Darby Malaysia Berhad Pflanzenfettmischung und esswaren, die solch eine fettmischung enthalten
ES2319054B1 (es) 2007-08-06 2010-02-12 Gp Pharm S.A. Composicion farmaceutica oral de desmopresina.
US8673841B2 (en) * 2008-03-31 2014-03-18 Ferring B.V. Oxytocin analogues
CN104013569A (zh) * 2008-10-15 2014-09-03 精达制药公司 高浓缩药物颗粒、制剂、混悬剂及其应用

Also Published As

Publication number Publication date
JP2017048226A (ja) 2017-03-09
CA2812510A1 (en) 2012-04-05
TW201605466A (zh) 2016-02-16
RU2737264C2 (ru) 2020-11-26
WO2012042371A3 (en) 2013-04-04
BR122021001123B1 (pt) 2021-05-18
CN107080832A (zh) 2017-08-22
RS62873B1 (sr) 2022-02-28
AU2011309762B2 (en) 2014-07-17
CN103124554A (zh) 2013-05-29
PT3222272T (pt) 2022-01-27
TW201219051A (en) 2012-05-16
TWI661834B (zh) 2019-06-11
BR112013007362B1 (pt) 2021-05-25
HK1246170A1 (zh) 2018-09-07
PT3246018T (pt) 2022-01-13
IL245328A0 (en) 2016-06-30
IL225238B (en) 2018-07-31
CN104906032A (zh) 2015-09-16
KR102102664B1 (ko) 2020-04-22
ES2637988T3 (es) 2017-10-18
EP3936117A1 (en) 2022-01-12
ES2902418T3 (es) 2022-03-28
DK3222272T3 (da) 2022-01-24
HRP20211969T1 (hr) 2022-03-18
JP2013543492A (ja) 2013-12-05
WO2012042371A2 (en) 2012-04-05
MX2013003365A (es) 2013-07-29
JOP20180102A1 (ar) 2019-01-30
TWI746951B (zh) 2021-11-21
PL3222272T3 (pl) 2022-03-07
HUE034367T2 (en) 2018-02-28
SI2621468T1 (sl) 2017-10-30
US20230124105A1 (en) 2023-04-20
CN107412728A (zh) 2017-12-01
TW201605465A (zh) 2016-02-16
RU2604690C2 (ru) 2016-12-10
JP6038797B2 (ja) 2016-12-07
CN107080832B (zh) 2021-05-07
NZ609719A (en) 2014-07-25
TW201940188A (zh) 2019-10-16
JOP20180102B1 (ar) 2022-03-14
TW201729797A (zh) 2017-09-01
LT2621468T (lt) 2017-11-27
PT2621468T (pt) 2017-09-08
PL2621468T3 (pl) 2017-11-30
TWI750934B (zh) 2021-12-21
US20130210746A1 (en) 2013-08-15
CY1119245T1 (el) 2018-02-14
MX352949B (es) 2017-12-15
JOP20180103B1 (ar) 2022-03-14
RU2013112666A (ru) 2014-11-10
HUE057187T2 (hu) 2022-04-28
DK2621468T3 (en) 2017-09-11
IL225238A0 (en) 2013-06-27
TWI680773B (zh) 2020-01-01
RU2016143751A3 (pt) 2020-01-16
US20170106044A1 (en) 2017-04-20
IL245326A0 (en) 2016-06-30
EP3246018B1 (en) 2021-11-03
TWI650134B (zh) 2019-02-11
TW202112389A (zh) 2021-04-01
RS56220B1 (sr) 2017-11-30
JO3400B1 (ar) 2019-10-20
EP3222272A1 (en) 2017-09-27
LT3222272T (lt) 2021-12-27
EP2621468A2 (en) 2013-08-07
IL245328B (en) 2022-04-01
JP6250770B2 (ja) 2017-12-20
KR20130136467A (ko) 2013-12-12
SI3246018T1 (sl) 2022-02-28
AU2011309762A1 (en) 2013-04-04
CY1124924T1 (el) 2023-01-05
TWI532507B (zh) 2016-05-11
PL3246018T3 (pl) 2022-05-02
DK3246018T3 (da) 2022-01-17
EP3222272B1 (en) 2021-11-03
EP3246018A1 (en) 2017-11-22
SI3222272T1 (sl) 2022-01-31
US9566311B2 (en) 2017-02-14
RU2016143751A (ru) 2018-12-18
KR101919119B1 (ko) 2018-11-15
HUE056835T2 (hu) 2022-03-28
JOP20180103A1 (ar) 2019-01-30
KR20180123599A (ko) 2018-11-16
ES2905561T3 (es) 2022-04-11
HRP20171256T1 (hr) 2017-10-20
IL245326B (en) 2021-04-29
US20170106043A1 (en) 2017-04-20
EP2621468B1 (en) 2017-06-14

Similar Documents

Publication Publication Date Title
BR112013007362A2 (pt) composição farmacêutica
SMT201600350B (it) Composizioni farmaceutiche
MX345514B (es) Composiciones pesticidas.
PA8827101A1 (es) Derivados de indazoles sustituidos con fenilo o piridinilo
DK2640893T4 (da) Sammensætninger
CO6980625A2 (es) Composiciones que generan perácidos
CR20140468A (es) Inhibidores de diacilglicerol aciltransferasa 2
UY33906A (es) Composiciones herbicidas que comprenden topramezona
DOP2013000307A (es) Antagonistas de trpv4
CR20150132A (es) Profármacos de aminoquinazolina inhibidora de cinasa
BR112014032759A2 (pt) composições lipídicas de racecadotril
BR112013014612A2 (pt) composições moc
CO6801722A2 (es) Composiciones farmacéuticas
BRPI0914940A8 (pt) Composições nutritivas contendo punicalaginas
BR112013011404A2 (pt) composições elastoméricas que resistem à desintegração
FR2965705B1 (fr) Compositions d'edulcorants
ATE533477T1 (de) Pharmazeutische zusammensetzungen enthaltend irbesartan
BR112013029778A2 (pt) composição farmacêutica que compreende fexofenadina
HK1151718A1 (en) Flupentixol compositions
TR201002878A2 (tr) Sefpodoksim proksetil içeren farmasötik bileşimler.
CR20150028A (es) Derivados de ariletinilo
CR20140531A (es) Derivados de ariletinilo
DK2935530T3 (da) Fischer-tropsch-afledte brændstofsammensætninger
UY35004A (es) Forma amorfa estabilizada de la agomelatina, su procedimiento de preparación y las composiciones farmacéuticas que la contienen
BR112013025766A2 (pt) composições farmacêuticas de liberação modificada de desvenlafaxina

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 29/09/2011, OBSERVADAS AS CONDICOES LEGAIS.